Document is current
Any future updates will be listed below
-
Authors
Ascierto, Paolo A https://orcid.org/0000-0002-8322-475X
Schadendorf, Dirk
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04339062 at ClinicalTrials.govnct03969004 at ClinicalTrials.govDocuments that mention this clinical trial
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082
Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
https://doi.org/10.1200/jco.23.01498
Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.9519
Acute Kidney Injury in Critically Ill Patients with Cancer
https://doi.org/10.2215/cjn.15681221
nct03833167 at ClinicalTrials.govDocuments that mention this clinical trial
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
nct04632433 at ClinicalTrials.govDocuments that mention this clinical trial
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
nct03666325 at ClinicalTrials.govDocuments that mention this clinical trial
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082
NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma.
https://doi.org/10.1200/jco.2023.41.16_suppl.9576
nct03944941 at ClinicalTrials.govDocuments that mention this clinical trial
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082
nct03521830 at ClinicalTrials.govDocuments that mention this clinical trial
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma
https://doi.org/10.1200/jco-25-00759
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082
nct02834013 at ClinicalTrials.govDocuments that mention this clinical trial
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
https://doi.org/10.1136/jitc-2021-004434
Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade
https://doi.org/10.1136/jitc-2023-007463
nct04679480 at ClinicalTrials.govDocuments that mention this clinical trial
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with <i>CD274</i> (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database
https://doi.org/10.1136/jitc-2024-010130
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix
https://doi.org/10.1136/jitc-2025-012805
Outcomes of Patients With Rare Cancers Treated With Combination Immune Checkpoint Inhibitors With and Without Previous Anti–PD-1/L1 Exposure: National Cancer Institute/SWOG S1609
https://doi.org/10.1200/oa-25-00110
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
https://doi.org/10.1136/jitc-2020-001532
Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609)
https://doi.org/10.1136/jitc-2025-013260
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.
https://doi.org/10.1200/jco.2023.41.16_suppl.5517
Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort
https://doi.org/10.1136/jitc-2025-011760
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors
https://doi.org/10.1136/jitc-2024-009128
Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?
https://doi.org/10.1136/ijgc-2022-003719
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
https://doi.org/10.1136/jitc-2024-009074
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48).
https://doi.org/10.1200/jco.2023.41.16_suppl.e16330
795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
https://doi.org/10.1136/jitc-2020-sitc2020.0795
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
https://doi.org/10.1136/jitc-2021-002990
Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
https://doi.org/10.1136/jitc-2022-004669
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).
https://doi.org/10.1200/jco.2023.41.16_suppl.11516
Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response
https://doi.org/10.1136/bcr-2020-236242
616 Correlations between baseline tumor burden and overall survival in patients with rare cancers treated with immune checkpoint inhibitors (NCI/SWOG S1609)
https://doi.org/10.1136/jitc-2024-sitc2024.0616
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
https://doi.org/10.1136/jitc-2020-001999
nct04362711 at ClinicalTrials.govDocuments that mention this clinical trial
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082
Documents that mention this clinical trial
Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma
https://doi.org/10.1136/jitc-2022-005082
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals (N/A)
Sanofi Genzyme (N/A)
- License Information
